Items Tagged ‘Prostate Cancer’

July 12th, 2017

Is Lynparza a Precision Cancer Medicine for Prostate Cancer?

By

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells. Lynparza became the first PARP inhibitor medicine to […]

View full entry

Tags: lynparza, News, olaparib, PARP inhibitor, Precision Cancer Medicine, Prostate Cancer


June 7th, 2017

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

By

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months to 33 months according to the results of a clinical study featured at the 2017 American […]

View full entry

Tags: abiraterone, hormone refractory, metastatic prostate cancer, News, Prostate Cancer, zytiga


February 23rd, 2017

Unique Gene Signature Predicts Potentially Lethal Prostate Cancers

By

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs despite androgen-deprivation therapy. A team of scientists led by Irwin Gelman, PhD, Professor of Oncology in the Department of Cancer Genetics at Roswell Park Cancer Institute, has […]

View full entry

Tags: News, Prostate Cancer


October 3rd, 2016

Different Treatment Options Appear Equally Effective in Early Prostate Cancer

By

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide approximately the same survival rates at 10 years. Spread of cancer, however, was higher among those whose cancer was monitored until progression. These results were recently published […]

View full entry

Tags: active monitoring, early, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, prostatectomy, PSA, radiation, regimen, surgery


August 15th, 2016

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer

By

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently published in the Journal of Clinical Oncology. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. Recently, screening […]

View full entry

Tags: News, Prostate Cancer, PSA, risk, screening, Screening/Prevention Prostate Cancer


August 10th, 2016

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer

By

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have treatment options: active surveillance, also called watchful waiting, in which the cancer is monitored periodically to detect any changes, or active treatment […]

View full entry

Tags: Decision Counseling Program, News, pilot study, Prostate Cancer, watchful waiting


July 26th, 2016

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer

By

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States.  Metastatic prostate cancer refers […]

View full entry

Tags: cabozantinib, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer


June 13th, 2016

FDA Approves New Imaging Agent for Detection of Recurrent Prostate Cancer

By

The United States Food and Drug Administration (FDA) has approved Axumin (fluciclovine F 18), an radioactive agent, to be used in positron emission tomography (PET) imaging for the detection of recurrent prostate cancer. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. If prostate cancer recurs following initial […]

View full entry

Tags: Axumin, fluciclovine F 18, imaging, News, PET, Prostate Cancer, recurrence, Refactory/Recurrent Prostate Cancer, scan


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen


May 18th, 2016

Addition of Radiation Improves Survival in High-Risk Prostate Cancer

By

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were recently published in the journal of European Urology. Prostate cancer is the most frequently diagnosed cancer in men aside from skin cancer. An estimated 220,800 […]

View full entry

Tags: adt, androgen deprivation therapy, endrocrine treatment, ET, News, Prostate Cancer, radiation therapy


May 17th, 2016

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers

By

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently presented at the 2016 Annual Scientific Meeting of the American Urological Association (AUA). Over 200,000 men each year in the United States […]

View full entry

Tags: African American men, Chemotherapy, News, Prostate Cancer, radical prostatectomy, recurrence


April 25th, 2016

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer

By

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak with their healthcare providers if they experience any feelings of depression, as effective treatment […]

View full entry

Tags: adt, depression, Early Stage I-II (A-B) Prostate Cancer, News, Prostate Cancer, testosterone


March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

By

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly 70 percent, according to the results of a new study. There is a well-documented association between exposure to radiation […]

View full entry

Tags: Bladder Cancer, bowel cancer, carcinogenesis, Colon Cancer, exposure, Hodgkin's Lymphoma, News, Prostate Cancer, radiation therapy, Rectal Cancer, secondary cancer


March 9th, 2016

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer

By

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual Genitourinary Cancers Symposium. Low-grade prostate cancer refers to cancer that has not spread to distant sites in […]

View full entry

Tags: clinical trial, hypofractionated, Prostate Cancer, radiation


February 22nd, 2016

Xtandi® Improves Survival in Advanced Prostate Cancer

By

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men […]

View full entry

Tags: bicalutamide, casodex, Early Stage I-II (A-B) Prostate Cancer, enzalutamide, Locally Advanced Stage III (C) Prostate Cancer, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer, xtandi